Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors-Reference-Cited by-同舟云学术

Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors

Published:2015-06-18 Issue:4 Volume:33 Page:921-930
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Do Khanh,Speranza Giovanna,Chang Lun-Ching,Polley Eric C.,Bishop Rachel,Zhu Weimin,Trepel Jane B.,Lee Sunmin,Lee Min-Jung,Kinders Robert J.,Phillips Larry,Collins Jerry,Lyons John,Jeong Woondong,Antony Ramya,Chen Alice P.,Neckers Len,Doroshow James H.,Kummar Shivaani

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-015-0255-1.pdf

Reference15 articles.

1. Pratt WB (1998) The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 217(4):420–434

2. Sidera K, Patsavoudi E (2008) Extracellular HSP90: conquering the cell surface. Cell Cycle 7(11):1564–1568

3. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5(10):761–772. doi: 10.1038/nrc1716

4. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10(8):537–549. doi: 10.1038/nrc2887

5. Neckers L, Schulte TW, Mimnaugh E (1999) Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Investig New Drugs 17(4):361–373

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination therapy involving HSP90 inhibitors for combating cancer: an overview of clinical and preclinical progress;Archives of Pharmacal Research;2024-04-17

2. Molecular Pathways Governing the Termination of Liver Regeneration;Pharmacological Reviews;2024-03-04

3. Enhanced Therapeutic Effects of 177Lu-DOTA-M5A in Combination with Heat Shock Protein 90 Inhibitor Onalespib in Colorectal Cancer Xenografts;Cancers;2023-08-24

4. Structural and functional complexity of HSP90 in cellular homeostasis and disease;Nature Reviews Molecular Cell Biology;2023-07-31

5. Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours;Gastric Cancer;2023-03-13